Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2021

Solanki Hitendra S, Welsh Eric A, Fang Bin, Izumi Victoria, Darville Lancia, Stone Brandon, Franzese Ryan, Chavan Sandip, Kinose Fumi, Imbody Denis, Koomen John M, Rix Uwe, Haura Eric B

Abstract excerpt

PURPOSE: Covalent inhibitors of KRASG12C specifically target tumors driven by this form of mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance. Although several combination strategies have been shown to improve efficacy of KRASG12C inhibitors (KRASi), underlying mechanisms and predictive strategies for patient enrichment are less clear. EXPERIMENTAL DESIGN: We performed mass...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, Liquid
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Interaction Mapping

Share to Protein Interaction Maps

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 33619172
DOI: 10.1158/1078-0432.CCR-20-3872
PMCID: PMC9940280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.PMID 33619172Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity Read ↗

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of SotorasibSemantic proximity Read ↗

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.Semantic proximity Read ↗

SHP2 Inhibition Abrogates Adaptive Resistance to KRAS <sup>G12C</sup> -Inhibition and Remodels the Tumor Microenvironment of <i>KRAS</i> -Mutant TumorsSemantic proximity Read ↗

Overcoming KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerSemantic proximity Read ↗

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.Semantic proximity Read ↗

Early-stage lung adenocarcinoma is driven by an injury-associated, plastic cell state dependent on a KRAS-ITGA3-SRC axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.